Use of Remdesivir in Myasthenia gravis and COVID‐19

Volume: 41, Issue: 6, Pages: 546 - 550
Published: Apr 27, 2021
Abstract
Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID-19). Multiple agents have been studied for the management of the COVID-19, including remdesivir. To date, no published reports have evaluated the utilization of the antiviral remdesivir in...
Paper Details
Title
Use of Remdesivir in Myasthenia gravis and COVID‐19
Published Date
Apr 27, 2021
Volume
41
Issue
6
Pages
546 - 550
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.